Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally

Chowdhary, Anuradha; Sharma, Cheshta; Meis, Jacques F.

doi:10.1371/journal.ppat.1006290

Cited by 585 publications

(597 citation statements)

References 29 publications

Supporting

Mentioning

559

Contrasting

Unclassified

Order By: Relevance

“…C. auris was first described in Japan in 2009 (3), and has since been reported in 17 countries on five continents (2,4). Only four C. auris isolates from prior to 2009 were identified retrospectively among 15,271 isolates in a global candidemia registry (5), suggesting rapid global dispersal.…”

Section: Discussionmentioning

confidence: 99%

“…Although the first reported cases of C. auris were patients with chronic otomycosis (3,11), most subsequent cases have been healthcare-associated and involved candidemia or other invasive infections (2). Persistent candidemia (lasting up to three weeks after antifungal initiation) and high mortality rates have been observed (7).…”

Section: Auris Can Cause Invasive Diseasementioning

confidence: 99%

“…Fluconazole resistance exceeds 90% (5) and reduced susceptibility to voriconazole may approach 50% (2). Tentative breakpoints for the newer triazoles, posaconazole and isavuconazole, are not available, but low MICs suggest that they may have activity against C. auris (2).…”

Section: Treatment Options Are Limitedmentioning

confidence: 99%

“…Tentative breakpoints for the newer triazoles, posaconazole and isavuconazole, are not available, but low MICs suggest that they may have activity against C. auris (2). Resistance to amphotericin B occurs in up to 35% of isolates (5) and echinocandin resistance has been reported in 2-8% of isolates (2,5). Resistance to all three major classes of antifungals was reported in 4% of isolates (5).…”

Section: Treatment Options Are Limitedmentioning

confidence: 99%

See 3 more Smart Citations

First reported case of multidrug-resistant Candida auris in Canada

Schwartz

Hammond

2017

Canada Communicable Disease Report

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Auris Can Cause Invasive Diseasementioning

confidence: 99%

Section: Treatment Options Are Limitedmentioning

confidence: 99%

Section: Treatment Options Are Limitedmentioning

confidence: 99%

See 2 more Smart Citations

First reported case of multidrug-resistant Candida auris in Canada

Schwartz

Hammond

2017

Canada Communicable Disease Report

View full text Add to dashboard Cite

“…Conversely, C . haemulonii and Candida duobushaemulonii form pseudohyphae with blastoconidia and do not grow at 42°C . C .…”

Section: Laboratory Diagnosismentioning

confidence: 99%

Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases

Ong

Chen

Clark

et al. 2019

Internal Medicine Journal

View full text Add to dashboard Cite

Candida auris is an emerging drug‐resistant yeast responsible for hospital outbreaks. This statement reviews the evidence regarding diagnosis, treatment and prevention of this organism and provides consensus recommendations for clinicians and microbiologists in Australia and New Zealand. C. auris has been isolated in over 30 countries (including Australia). Bloodstream infections are the most frequently reported infections. Infections have crude mortality of 30–60%. Acquisition is generally healthcare‐associated and risks include underlying chronic disease, immunocompromise and presence of indwelling medical devices. C. auris may be misidentified by conventional phenotypic methods. Matrix‐assisted laser desorption ionisation time‐of‐flight mass spectrometry or sequencing of the internal transcribed spacer regions and/or the D1/D2 regions of the 28S ribosomal DNA are therefore required for definitive laboratory identification. Antifungal drug resistance, particularly to fluconazole, is common, with variable resistance to amphotericin B and echinocandins. Echinocandins are currently recommended as first‐line therapy for infection in adults and children ≥2 months of age. For neonates and infants <2 months of age, amphotericin B deoxycholate is recommended. Healthcare facilities with C. auris should implement a multimodal control response. Colonised or infected patients should be isolated in single rooms with Standard and Contact Precautions. Close contacts, patients transferred from facilities with endemic C. auris or admitted following stay in overseas healthcare institutions should be pre‐emptively isolated and screened for colonisation. Composite swabs of the axilla and groin should be collected. Routine screening of healthcare workers and the environment is not recommended. Detergents and sporicidal disinfectants should be used for environmental decontamination.

show abstract

Candida , Cryptococcus , and Other Yeasts of Medical Importance

Borman,

Johnson

2023

ClinMicroNow

View full text Add to dashboard Cite

Unicellular fungi which typically divide by budding have traditionally been referred to as yeasts. The rapidly expanding use of molecular identification strategies has permitted detailed phylogenetic analyses, allowing more accurate delineation of taxonomic boundaries and the reclassification of many yeast species and genera. Molecular identification approaches have also further added to the taxonomic complexity via the delineation of a number of cryptic species and species complexes in many traditional Candida species that can be separated only based on DNA sequencing analysis. The heterogeneous genus Candida belongs to the order Saccharomycetales within the ascomycetes. Rhodotorula spp. and species in the allied genus Cystobasidium share many similar physiologic and morphologic properties with Cryptococcus spp., as they are round to oval‐shaped, multilateral budding yeasts with capsules, although capsules, when present, are typically small. Carbohydrate antigens have provided useful targets for several commercial kits for the detection of disseminated candidiasis.

show abstract

Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally

Cited by 585 publications

References 29 publications

First reported case of multidrug-resistant Candida auris in Canada

First reported case of multidrug-resistant Candida auris in Canada

Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases

Candida , Cryptococcus , and Other Yeasts of Medical Importance

Contact Info

Product

Resources

About